El interés en corto de Senseonics Holdings da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Senseonics Holdings. Los datos de interés en corto se actualizan cada dos semanas.

Senseonics Holdings (AMEX:SENS) Bolsa, Informe de interés en corto

Senseonics Holdings

Senseonics Holdings Inc is a medical technology company. It is focused on the design, development, and commercialization of glucose monitoring system, which helps people to manage their diabetes community with differentiated, long-term implantable glucose management technology. Its products and services include a Continuous glucose monitoring system, Sensor, Smart transmitter, and Mobile app. The firm has a Glucose monitoring product segment. The majority of the revenue is generated outside of the United States.

Senseonics Holdings Inc

SENSO

SENSHU ELECTRIC CO LTD by SENSHU ELECTRIC CO LTD.

SENSHU IKEDA HLDGS INC by Senshu Ikeda Holdings Inc.

SENSIO TECHNOLOGIES INC by SENSIO Technologies Inc.

SENSYNE HEALTH LTD by Sensyne Health Ltd.

SENSEN NETWORKS LTD by SenSen Networks Limited

SenSen Networks Ltd

SENSASURE TECHNOLGIES INC by SensaSure Technologies, Inc.

Sensasure Technologies Inc

Sensata Technologies Holding plc Ordinary Shares

Sensata Technologies Holding PLC

SENSE TECHS INC ORD by Sense Technologies, Inc.

Sense Technologies Inc

SENSETIME GRP INC CL B by SENSETIME GROUP INC.

SenseTime Group Inc

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics Inc

SENSIBLE MEATS INC by SENSIBLE MEATS INC.

Sensible Meats Inc

Sensient Technologies Corporation Common Stock

Sensient Technologies Corp

Senstar Technologies Corporation - Common Shares

Senstar Technologies Corp

Sensus Healthcare Inc

Evercore ISI Group analyst Josh Schimmer downgrades Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) from Outperform to In-Line and maintains the price target from $5 to $5.

News

Downgrades

Price Target

Analyst Ratings

SPRO

Evercore ISI Group Downgrades Spero Therapeutics to In-Line, Maintains Price Target to $5

Telsey Advisory Group analyst Joseph Feldman maintains Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) with a Market Perform and maintains $75 price target.

DLTR

Telsey Advisory Group Maintains Market Perform on Dollar Tree, Maintains $75 Price Target

Following a sluggish session on Thursday and a fall on Wednesday after the Fed&#8217;s <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42563299/feds-powell-shocks-markets-its-a-new-phase-were-significantly-closer-to-neutral">hawkish</a> rate cut, Wall Street is now bracing for Friday&#8217;s &#8220;Triple Witching&#8221; session which is slated to see about $6.6 trillion options to expire.
What Happened: The &#8220;Triple Witching&#8221; hour is a quarterly event that occurs during the final hour of trade on the third Friday of March, June, September, and December. During this period, contracts for stock index futures, stock index options, and stock options all expire at the same time.
According to the Singapore-based broker, uSMART, Friday, Dec. 20 marks the notorious &#8216;Triple Witching&#8217; day, when the total options contracts worth $5.2 trillion on the S&amp;P 500 index, $710 billion worth of contracts on single stocks and $735 billion worth of contracts on the Nasdaq 100, Russell 200 and others are set to expire.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f4a1;This Friday&#39;s &quot;Triple Witching Day&quot; is expected to be the largest options expiration day in history, with a total of over $6 trillion in options tied to stocks, exchange-traded funds (ETFs), and indices set to expire. <a href="https://twitter.com/hashtag/stocks?src=hash&amp;ref_src=twsrc%5Etfw">#stocks</a> <a href="https://twitter.com/hashtag/ETFs?src=hash&amp;ref_src=twsrc%5Etfw">#ETFs</a> <a href="https://t.co/ExaqHgfzX5">pic.twitter.com/ExaqHgfzX5</a>
&mdash; uSMART (@usmartsg) <a href="https://twitter.com/usmartsg/status/1870010390471684367?ref_src=twsrc%5Etfw">December 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The total $6.6 trillion worth of option contracts can be further divided into four categories. Here&#8217;s what they include:
<ul>
<li>About $4.5 trillion notional worth of index options contracts.</li>
<li>$685 billion notional worth of options on futures.</li>
<li>$745 billion notional worth of options on exchange-traded funds.</li>
<li>$710 billion notional worth of contracts on single stocks.</li>
</ul>
&#8220;The timing of buying the dip is complicated by options expiration tomorrow and Christmas next week, but a recovery by the end of the year would not surprise anyone,&#8221; said Louis Navellier, founder of Navellier &amp; Associates.
See Also: <a href="https://www.benzinga.com/24/12/42610441/nikes-new-ceo-says-we-lost-our-obsession-with-sport-as-he-rebukes-old-strategies-on-performance-marketing-isolation-of-wholesalers-aims-to-create-demand">Nike&#8217;s New CEO Blames Promotions For Declining Profits, Says Turnaround Efforts May Hurt As Company Moves To Clear Excess Inventory</a>
Why It Matters: This &#8220;Triple Witching&#8221; convergence can lead to heightened market volatility as traders close, roll over, or offset their expiring contracts, often resulting in unusual price movements and increased trading volumes.
Looking back at the last few triple-witching events, the S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), has struggled during these high-stakes trading days.
<ul>
<li>Sept. 20, 2024: Decline of 0.2%.</li>
<li>Jun. 21, 2024: Decline of 0.5%.</li>
<li>Mar. 15, 2024: Decline of 1%.</li>
<li>Dec. 15, 2023: Decline of 0.6%.</li>
</ul>
Tech stocks, represented by the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), fell in the last three triple-witching occasions, dropping 0.19% in September, 0.8% in June and 1.2% in March, while surging 0.5% in December 2023.
Price Action: U.S. stock futures declined, ahead of the &#8216;Triple Witching&#8217; Friday. All four major indices were trading lower.
In premarket trading, the SPDR S&amp;P 500 ETF Trust was down 1.05% to $579.97 and the Invesco QQQ Trust ETF fell 1.26% to $507.68, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-1.20%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.75%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.59%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.24%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42610958/expecting-up-to-four-fed-rate-cuts-in-2025-says-this-analyst-despite-hawkish-powell-saying-it-was-close-on-the-decision-to-cut-or-not-heres-why">Hawkish Powell Aside, This Analyst Expects 4 Fed Rate Cuts In 2025: Here&#8217;s Why</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Futures

Options

Markets

The $6.6 Trillion Question: Can Markets Weather Triple Witching And Hawkish Fed Signals? Here's What This Analyst Says

Evercore ISI Group analyst Gavin Clark-Gartner downgrades Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) from Outperform to In-Line and lowers the price target from $15 to $6.

CABA

Evercore ISI Group Downgrades Cabaletta Bio to In-Line, Lowers Price Target to $6

Novo Nordisk Spokesperson Said Regulatory Submission Of Cagrisema Is Expected Towards The End Of 2025

Novo Nordisk Spokesperson Said Cagrisema Trial Permitted Dose Reductions; Statistically Significant Results Were Achieved Even Though Only 57% Of Patients On Cagrisema Reached The Highest Dose

Oppenheimer analyst Leland Gershell initiates coverage on Rhythm Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) with a Outperform rating and announces Price Target of $76.

Initiation

RYTM

Oppenheimer Initiates Coverage On Rhythm Pharmaceuticals with Outperform Rating, Announces Price Target of $76

Cable One currently owns a 45% stake in MBI, and affiliates of GTCR LLC ("GTCR") and MBI management own the balance of MBI. The amendments provide Cable One with enhanced ability to control the timing for acquiring the 55% interest it does not currently own pursuant to the put right held by GTCR, with any such acquisition to occur no earlier than October 1, 2026 unless Cable One elects to close the transaction at an earlier date.

CABO

Cable One Announced That It Has Amended The Terms Of Its Strategic Investment In Mega Broadband Investments Holdings To Provide Enhanced Timing Flexibility For Cable One's Potential Acquisition Of Full Ownership Of MBI

Canaccord Genuity analyst Joseph Vafi maintains Blend Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLND#NYSE">BLND</a>) with a Buy and maintains $5.75 price target.

BLND

Canaccord Genuity Maintains Buy on Blend Labs, Maintains $5.75 Price Target

RSLS

Reshape Lifesciences Inc Files For Offering Of Up To 2.1M Shares Of Common Stock By Selling Stockholder

BiXin is a manufacturer of chillers, heat pumps, heat-recovery solutions and air-handling units. Focused on expanding the Vertiv chiller family, the acquisition strengthens Vertiv's portfolio of critical technologies and solutions in support of high-performance compute and AI applications globally.

Vertiv's Chinese Subsidiary Acquires Certain Assets And Technologies Of BiXin Energy Technology; No Terms Disclosed

EXTO

Almacenes Exito Plans To Delist American Depositary Shares From the New York Stock Exchange And Subsequent Arrangements, Company Says It Is Not Driven By Costs Or Concerns Regarding Compliance With The Requirements And Regulations

HC Wainwright &amp; Co. analyst Amit Dayal initiates coverage on AirJoule Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRJ#NASDAQ">AIRJ</a>) with a Buy rating and announces Price Target of $12.

AIRJ

HC Wainwright & Co. Initiates Coverage On AirJoule Technologies with Buy Rating, Announces Price Target of $12

Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) with a Buy and lowers the price target from $30 to $20.

SONN

Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $20

HC Wainwright &amp; Co. analyst Heiko Ihle reiterates Largo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGO#NASDAQ">LGO</a>) with a Buy and maintains $4.2 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Largo, Maintains $4.2 Price Target

On Thursday, December 19, U.S. markets closed mixed after initial gains faded. Stocks mainly remained flat as the Fed forecasted fewer 2025 rate cuts and higher inflation. Jobless claims fell, and Q3 GDP was revised to 3.1%, supporting the Fed&#8217;s view. The Dow ended its 10-session losing streak.
The U.S. economy grew 3.1% in Q3, revised from 2.8% while existing home sales rose 4.8% in November to 4.15 million. Initial jobless claims fell by 22,000 to 220,000 in early December, below estimates of 230,000.
Most S&amp;P 500 sectors ended lower, led by losses in materials, real estate, and energy. In contrast, utilities and financials outperformed, closing the session higher.
The Dow Jones Industrial Average was up 0.04% and closed at 42,342.24, the S&amp;P 500 closed lower by 0.09% at 5,867.08, and the Nasdaq Composite slipped 0.10% to finish at 19,372.77.
Asia Markets Today
<ul>
<li>On Friday, Japan&#8217;s Nikkei 225 declined 0.22% and ended the session at 38,723.50, led by losses in the Communication, Steel, and Transportation Equipment sectors shares.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 fell 1.24% and ended the day at 8,067.00, led by losses in the Consumer Discretionary, Financials and Gold sectors.</li>
<li>India&#8217;s Nifty 50 slid 1.35% to 23,627.45, and the Nifty 500 was down 1.82%, closing at 22,337.55. Losses in the Real Estate, Power, and Capital Goods sectors led to the declines.</li>
<li>China&#8217;s Shanghai Composite fell 0.06% to close at 3,368.07, and the Shenzhen CSI 300 declined 0.45%, finishing the day at 3,927.74.</li>
<li>Hong Kong&#8217;s Hang Seng was down 0.16% and closed the session at 19,720.70.</li>
</ul>
Eurozone at 05:30 AM ET
<ul>
<li>The European STOXX 50 index was down 1.35%.</li>
<li>Germany&#8217;s DAX slid 1.42%.</li>
<li>France&#8217;s CAC fell 1.30%.</li>
<li>U.K.&#8217;s FTSE 100 index traded lower by 1.09%.</li>
<li>European shares headed for their worst week in three months as Trump&#8217;s tariff threats on the EU rattled investors already concerned about U.S. rates. The STOXX 600 fell 1.1%, with major indices and sectors declining sharply, including banks and miners.</li>
</ul>
Commodities at 05:30 AM ET
<ul>
<li>Crude Oil WTI was trading lower by 2.69% at $68.67/bbl, and Brent was down 0.99% at $72.16/bbl.</li>
<li>Oil prices declined this week due to concerns about slowing demand growth in the coming years, particularly from China. The market was further pressured by a stronger dollar and ongoing revisions to demand forecasts by OPEC and its allies.</li>
<li>Natural Gas rose 1.95% to $3.654.</li>
<li>Gold was trading higher by 0.49% at $2,620.71, Silver was down 0.44% to $29.277 and rose 0.02% to $4.0780.</li>
</ul>
U.S. Futures at 05:30 AM ET
Dow futures were down 0.58%, S&amp;P 500 futures fell 0.82% and Nasdaq 100 futures declined 1.18%.
Forex at 05:30 AM ET
<ul>
<li>The U.S. dollar index was down 0.24% to 108.15, the USD/JPY fell 0.44% to 156.73, and the USD/AUD rose 0.12% to 1.6050.</li>
<li>The dollar neared a two-year high, set for its third weekly gain amid expectations of prolonged high U.S. rates. Global currencies weakened, with the yen and euro under pressure.</li>
</ul>
Image via Shutterstock

Asia

Emerging Markets

Eurozone

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

US Dollar Hits New Higher While Asia And Europe Markets Slide, Oil Drops On China Demand Fears - Global Markets Today While US Slept

Wedbush analyst Nick Setyan maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Outperform and raises the price target from $200 to $220.

Wedbush Maintains Outperform on Darden Restaurants, Raises Price Target to $220

Stephens &amp; Co. analyst Jim Salera maintains Darden Restaurants (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) with a Equal-Weight and raises the price target from $164 to $175.

Stephens & Co. Maintains Equal-Weight on Darden Restaurants, Raises Price Target to $175

Telsey Advisory Group analyst Cristina Fernandez downgrades Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) from Outperform to Market Perform and lowers the price target from $93 to $80.

Telsey Advisory Group Downgrades Nike to Market Perform, Lowers Price Target to $80

Fennec Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FENC#NASDAQ">FENC</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/FRX#TSX">FRX</a>), a specialty pharmaceutical company, today announced that Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, has received positive final draft guidance from National Institute for Health and Care Excellence (NICE) recommending PEDMARQSI for the prevention of cisplatin-induced hearing loss in patients (aged 1 month to 17 years) with localized, non-metastatic, solid tumors.
PEDMARQSI&nbsp;is the first and only approved therapy in the EU and&nbsp;U.K. for the prevention of ototoxicity, or hearing loss, induced by cisplatin chemotherapy in patients 1 month to &lt;18 years of age with localized, non-metastatic solid tumors. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine will commercialize&nbsp;PEDMARQSI&#xAE;&nbsp;in&nbsp;Europe,&nbsp;Australia, and New Zealand.
"Securing access to PEDMARQSI is a critical milestone for the cancer community in England and Wales to help reduce the risk of ototoxicity, or permanent hearing loss, associated with cisplatin treatment," said&nbsp;Jeff Hackman, chief executive officer and director of Fennec Pharmaceuticals. "We congratulate Norgine on their collaboration with NICE to reach this important agreement that recognizes the value of ototoxicity intervention as part of the cancer treatment journey."
Under the terms of the <a href="https://investors.fennecpharma.com/news-releases/news-release-details/fennec-pharmaceuticals-and-norgine-enter-exclusive-licensing">previously announced</a> exclusive licensing agreement with Norgine, Fennec received approximately $43 million in an upfront payment and will receive up to approximately $230 million in additional commercial and regulatory milestone payments along with double-digit tiered royalties on net sales of PEDMARQSI starting in the mid-teens and growing to the mid-twenties.

Government

Regulations

FENC

TSX:FRX

Fennec's PEDMARQSI Gains National Institute for Health and Care Excellence Support, Offers Hope for Young Patients

Apple reportedly tests a blood sugar app

Senseonics Holdings ( ($SENS) ) just unveiled an update. Senseonics Holdings, Inc. has updated its equity distribution agreement with Goldman Sachs...

Senseonics Holdings Expands Equity and Financial Strategy

BTIG analyst Marie Thibault reiterated a Hold rating on Senseonics Holdings (SENS – Research Report) yesterday. The company's shares closed yesterd...

BTIG Keeps Their Hold Rating on Senseonics Holdings (SENS)

Senseonics Q3 2024 Earnings Preview

Here are the major earnings after the close today

Reports Q3 revenue $4.26M, consensus $4.08M. "We received FDA approval for Eversense 365 in the third quarter, and Mercy completed the first commer...

Senseonics reports Q3 EPS (4c), consensus (3c)

The company said, "Senseonics (SENS) expects full-year 2024 global net revenue to be approximately $22 million as we begin to transition U.S. patie...

Senseonics narrows FY24 revenue view to 422M from $22M-$24M, consensus $22.18M

Senseonics Holdings, Inc. (SENS) Q3 2024 Earnings Call Transcript

An update from Senseonics Holdings ( ($SENS) ) is now available. Senseonics Holdings, Inc. is revolutionizing diabetes management with the Eversens...

Senseonics Holdings Expands with Innovative Diabetes Solutions

16:10 EST Senseonics (SENS) files to sell 45.71M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, ...

Comments

Senseonics Holdings

Interés en corto

Senseonics Holdings (AMEX:SENS) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL